Pan-cancer analysis identifies *CDCA3* as a novel prognostic marker associated with immune infiltration in lung adenocarcinoma through bioinformatics analysis

Hao Yang[1,2]^, Xueqiang Wei[3], Liren Zhang[1,2], Li Xiang[2], Ping Wang[2]

[1]Kunming Medical University, Kunming, China; [2]Department of Thoracic Surgery, the Second Affiliated Hospital of Kunming Medical University, Kunming, China; [3]Department of Thoracic Surgery I, the Third Affiliated Hospital of Kunming Medical University/Yunnan Cancer Hospital, Kunming, China

Contributions: (I) Conception and design: H Yang; (II) Administrative support: P Wang; (III) Provision of study materials or patients: H Yang, X Wei, L Xiang; (IV) Collection and assembly of data: H Yang, L Zhang; (V) Data analysis and interpretation: All authors; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: Ping Wang. Department of Thoracic Surgery, The Second Affiliated Hospital of Kunming Medical University, No. 374, Dianmian Road, Kunming 650118, China. Email: wangping2467@aliyun.com.

Background: Lung adenocarcinoma (LUAD) is the most common subtype of lung malignancy. However, the expression of cell division cycle-associated protein-3 (*CDCA3*) and its significance in LUAD remain unclear. In this study, we investigated the functional role of *CDCA3* in LUAD through bioinformatics analysis and expected to provide a new direction for clinical treatment.

Methods: The expression of *CDCA3* was analyzed by online database. The association between the expression of *CDCA3* and clinical parameters with LUAD was explored in TCGA. Survival and independent prognostic analysis were performed by TCGA database and the GSE30219 and GSE31210 datasets. Furthermore, Enrichment analyses were conducted to analyze the functions of *CDCA3*. Afterward, the relationship between *CDCA3* and immune infiltration was investigated. Additionally, a competing endogenous RNA (ceRNA) regulatory network related to *CDCA3* was constructed. Finally, *CDCA3* expression was validated in clinical tissues by immunohistochemistry (IHC), real-time quantitative reverse transcriptase polymerase chain reaction (qRT-PCR), and western blotting (WB).

Results: *CDCA3* expression was upregulated in 20 tumors and was significantly higher in LUAD compared with normal tissues in3 datasets. In addition, *CDCA3* was significantly correlated with age, gender, stage, N, and smoking status. Kaplan-Meier survival curves showed that LUAD samples with higher *CDCA3* expression were associated with poorer overall survival (OS) and disease-free survival (DFS). Univariate Cox regression analysis showed that the p value of *CDCA3* expression was less than 0.05 (P<0.05) and it appeared in the results of multivariate Cox regression analysis (HR ≥1), indicating that *CDCA3* can be used as an independent prognostic factor for LUAD. Intriguingly, Gene Set Enrichment Analysis (GSEA) suggested that *CDCA3* was correlated with DNA-related terms and metabolic-related pathways in LUAD. *CDCA3* expression was correlated with four immune scores and 14 immune cells in different groups. Next, a ceRNA network was constructed with *CDCA3*, and the experimental results of IHC, qRT-PCR, and WB were consistent with the bioinformatic analysis.

Conclusions: *CDCA3* could serve as a prognostic biomarker for LUAD.

Keywords: Cell division cycle-associated protein-3 (*CDCA3*); lung adenocarcinoma; prognosis; competing endogenous RNA (ceRNA)

---

^ ORCID: 0000-0002-3026-9866.

Introduction

Lung cancer is a malignant tumor with a high incidence and mortality rate worldwide (1,2). In China, lung cancer is the most lethal tumor for men and the second most lethal tumor for women after breast cancer. In 2019, Chinese cancer registration data showed 787 thousand newly reported cases of lung cancer, with an incidence rate of 57.26/10 million. Moreover, there were 631 thousand deaths from lung cancer, with a mortality rate of 45.87/10 million (3,4). Thus, lung cancer is a serious threat to the health of Chinese residents. Lung cancer is divided into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) according to different pathological types. Lung adenocarcinoma (LUAD) is the major subtype of NSCLC, accounting for more than 40% of cases (5). Moreover, most patients are in the later stage of the LUAD when diagnosed. Although developments in biomarkers, targeted gene therapy, and immuno-oncology have improved the clinical management of patients with advanced NSCLC, the 5-year survival rate of patients with lung cancer is still less than 20%, and the survival rate after metastasis is less than 3% due to blood metastasis, lymph node metastasis, and drug resistance during treatment (4,6). This undoubtedly increases the difficulty of treatment for doctors. Thus, there is an urgent need to explore the pathogenesis of LUAD and identify biomarkers with good specificity and sensitivity.

Cell division cycle-associated protein-3 (*CDCA3*), also known as Tom-1, is located on human chromosome 12p13. This gene has a total length of 7,271 bp and contains 6 exons. The protein contains 286 coding amino acids (7) and is one of the key proteins necessary for the activation of cyclin dependent kinase 1 (*CDK1*)/cyclin B and the entry of cells into mitosis. The excessive proliferation of cells is related to an abnormal cell cycle and promotes the formation of malignant tumors. Therefore, this gene has important research value in the occurrence and development of tumors. Studies have reported that *CDCA3* is involved in a variety of tumors, such as hepatocellular carcinoma (HCC) (8,9), gastric cancer (GC) (10), bladder cancer (BC) (11), and prostate cancer (PC) (12) In Hepatocellular Carcinoma, researchers pointed that *CDCA3* was a novel prognostic biomarker and associated with immune infiltration. However, there was few study on the role of *CDCA3* could act as a prognostic biomarkers in LUAD from bioinformatics Perspective. Thus, the role of *CDCA3* in LUAD was discussed here (13).

In the first stage of this study, the different expression of *CDCA3* in LUAD and normal tissues was assessed by bioinformatics. Then, the correlation between the expression of *CDCA3* and clinicopathological parameters was analyzed. Independent prognostic analysis, single gene enrichment analysis, and functional exploration of *CDCA3* were also carried out. In addition, the correlation between *CDCA3* and the tumor microenvironment was analyzed and a competing endogenous RNA (ceRNA) network was constructed using The Cancer Genome Atlas (TCGA) database. Next, the mRNA and protein expression levels of *CDCA3* were preliminarily verified by clinical tissue samples, and the results were found to be consistent with bioinformatics analysis. Our findings showed that the expression of *CDCA3* was upregulated in multiple tumors, including LUAD, and related to clinical parameters such as tumor stage. High expression of *CDCA3* was negatively correlated with overall survival (OS) and disease-free survival (DFS), which suggested that *CDCA3* expression could be used as an independent prognostic factor for LUAD. Furthermore, Cell-type Identification by Estimating Relative Subsets of RNA Transcripts (CIBERSORT) analysis found that *CDCA3* was correlated with 14 immune cells, and Tumor Immune Estimation Resource (TIMER) analysis found that *CDCA3* was correlated with 4 immune cells. This research explored the relationship between *CDCA3* and LUAD from multiple perspectives with the aim of providing a promising therapeutic target for the prevention and treatment of LUAD. We present the following article in accordance with the REMARK reporting checklist (available at https://tcr.amegroups.com/article/view/10.21037/tcr-22-1901/rc).

Methods

Data source

This study mainly through bioinformatics analysis to download mRNA expression data and survival and clinical

information of 59 normal samples and 534 LUAD samples were extracted from the TCGA database. Among the 534 LUAD samples, a total of 476 LUAD samples with both survival and clinical information were used for the survival analysis. The GSE30219, GSE18842, and GSE31210 datasets were obtained from the Gene Expression Omnibus (GEO) database. The GSE30219 dataset containing 14 normal samples and 85 LUAD samples was used for the differential expression and survival analyses. The GSE18842 dataset containing 45 normal samples and 46 LUAD samples was used for the differential expression analysis. Moreover, the GSE31210 dataset containing 226 LUAD samples was used for the survival analysis.

The expression of CDCA3 in LUAD

The TIMER database (http://timer.cistrome.org/) and the Gene Expression Profiling Interactive Analysis (GEPIA) database (http://gepia.cancer-pku.cn/) were used to search the mRNA expression of *CDCA3* in different cancers. Furthermore, the expression of *CDCA3* was identified in normal and LUAD samples in the TCGA database and the GSE30219 and GSE18842 datasets.

Correlation between CDCA3 expression and clinicopathological characteristics

LUAD patients in the TCGA database were separated into 2 groups according to age (<60 and ≥60), gender (female and male), stage (stage I-II and stage III-IV), N (N0 and N+), and smoking status (<40 and ≥40). The expression of *CDCA3* was then compared in these groups.

Independent prognostic analysis

OS and the DFS were investigated with respect to *CDCA3* gene expression in the TCGA database and the GSE30219 and GSE31210 datasets. OS and DFS curves were drawn using the Kaplan-Meier method. To determine whether *CDCA3* expression was significant with respect to other clinical characteristics, independent prognostic analysis was conducted using the TCGA database and the GSE30219 and GSE31210 datasets. The potential prognostic factors were screened by Cox analysis. Correlations between *CDCA3* expression and survival and other clinical characteristics of patients were confirmed by using multivariate Cox analysis.

Single gene GSEA of CDCA3

Gene Set Enrichment Analysis (GSEA) was performed to analyze the Gene Ontology (GO) functions and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways enrichment of CDCA3 using the "clusterProfiler" package in R (The R Foundation for Statistical Computing, Vienna, Austria) (14). The correlation coefficients between the expression levels of all genes and the *CDCA3* gene were calculated, and conducted GSEA according to the correlation coefficient.

Relationship between CDCA3 expression and immunity

The "estimate" (15) installation package in R language was used to evaluate the immune score, tumor purity, and stromal score of LUAD samples from the TCGA database. In addition, the differences between immune cell subtypes were explored using the CIBERSORT algorithm. Next, the relationship between the level of *CDCA3* expression and immunity was explored in TIMER2.0 (http://timer.cistrome.org/).

CeRNA network construction

The differentially expressed mRNAs (DEmRNAs), long noncoding RNAs (DElncRNAs), and microRNAs (DEmiRNAs) were identified between LUAD and normal samples from the TCGA database by using the "limma" package (16) in R with |log$_2$FC| >1 and P<0.05. Next, the target miRNAs of *CDCA3* were predicted using the miRWalk database (http://mirwalk.umm.uni-heidelberg.de/). In accordance with ceRNA theory, miRNAs that negatively correlated with the expression trend of the *CDCA3* were screened out. Then, the Starbase website (http://starbase.sysu.edu.cn/) was used to predict the target lncRNAs of miRNA. Similarly, lncRNAs that negatively correlated with the expression trend of the above miRNAs were selected. Finally, a ceRNA regulatory network was constructed using the miRNAs, lncRNAs, and mRNAs and was visualized using Cytoscape software (The Cytoscape Consortium).

Experimental verification

The study was conducted in accordance with the

Declaration of Helsinki (as revised in 2013). The study was approved by the ethics committee of The Second Affiliated Hospital of Kunming Medical University (No. KYCS2022090), and informed consent was obtained from all patients. A total of 33 LUAD tissues and 33 normal tissues, which obtained from Department of thoracic surgery, the Second Affiliated Hospital of Kunming Medical University and were used for the immunohistochemistry (IHC) staining, mRNA expression, and western blotting (WB) of *CDCA3*. For IHC, LUAD tissue sections were detected with two-step detection kit (PV-9000, ZSGB-Bio, Beijing, China). Next, total RNA and complementary DNA (cDNA) synthesis were performed according to the manufacturer's instructions. Gene expression was calculated by $2^{-\Delta\Delta CT}$ method. The forward primer for *CDCA3* was 5'-AGTACACGAGCAAGAAGCCATT-3', and the reverse primer for *CDCA3* was 5'-GCAACAGGAGGA TCAGACAGA-3'. For WB, whole cell lysates were prepared by RIPA buffer, and then proteins were separated with sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) gel and transferred to polyvinylidene difluoride (PVDF) membranes. The proteins were incubated overnight with primary antibodies *CDCA3* (1:100 dilution, bs-7894R, LS-Bio, Beijing, China) and glyceraldehyde 3-phosphate dehydrogenase (*GAPDH*; 1:100 dilution, bs-13282R, FineTest, Wuhan, China). Next, secondary antibodies (1:100 dilution, #31001, PIERCE, USA) were incubated, and the chemiluminescent signals were detected using an ECL-Plus detection kit (#131023-60-4, BOC Sciences, USA).

Statistical analyses

The *CDCA3* expression of cancer and adjacent tissues was analyzed using the TIMER and GEPIA databases with P values and fold changes. The correlation between *CDCA3* expression and clinicopathological characteristics was compared using the chi-square test or the chi-square goodness of fit test. Analysis of OS and DFS was performed using Kaplan-Meier curves, log-rank test.

The factors with (P<0.05) in the univariate Cox regression analysis results were added in the multivariate Cox regression analysis. The factors appearing in the multivariate Cox regression results were considered to be an independent prognostic factors.

In this study, all boxplots were drawn by the R package "ggplot2" (17), and significance was calculated by the wilcox.test function in R. P values <0.05 were considered

statistically significant.

Results

The expression of CDCA3 in LUAD

To explore the correlation between the expression of *CDCA3* and cancer, *CDCA3* expression was estimated in different tumors and adjacent normal tissues. In the TIMER database, *CDCA3* expression was higher in bladder urothelial carcinoma (BLCA), breast invasive carcinoma (BRCA), cervical squamous cell carcinoma (CESC), cholangiocarcinoma (CHOL), colon adenocarcinoma (COAD), esophageal carcinoma (ESCA), glioblastoma multiforme (GBM), head and neck squamous cell carcinoma (HNSC), HPV-positive head and neck squamous cell carcinoma (HNSC-HPV+), kidney renal clear cell carcinoma (KIRC), kidney renal papillary cell carcinoma (KIRP), liver hepatocellular carcinoma (LIHC), LUAD, lung squamous cell carcinoma (LUSC), pancreatic adenocarcinoma (PAAD), prostate adenocarcinoma (PRAD), rectum adenocarcinoma (READ), stomach adenocarcinoma (STAD), thyroid carcinoma (THCA), and uterine corpus endometrial carcinoma (UCEC) tumors than in normal samples (*Figure 1A*). In the GEPIA database, *CDCA3* expression was higher in adrenocortical carcinoma (ACC), BLCA, BRCA, CESC, COAD, diffuse large B-cell lymphoma (DLBC), ESCA, GBM, HNSC, LIHC, LUAD, LUSC, ovarian cancer (OV), PAAD, READ, skin cutaneous melanoma (SKCM), STAD, thymoma (THYM), UCEC, and uterine carcinosarcoma (UCS) tumors than in normal samples (*Figure 1B*). Conversely, in the GEPIA database, *CDCA3* expression was lower in acute myeloid leukemia (LAML) tumors than in normal samples (*Figure 1B*). Subsequently, *CDCA3* expression was estimated between LUAD and normal samples in the TCGA database and the GSE30219 and GSE18842 datasets, and the expression levels of *CDCA3* were found to be significantly higher in LUAD compared to those in normal samples (*Figure 1C-1E*).

Correlation between CDCA3 expression and clinicopathological characteristics

To investigate the correlation between *CDCA3* expression and clinicopathological characteristics, TCGA samples were separated into 2 groups according to clinicopathological characteristics. As shown in *Figure 2*, *CDCA3* was significantly correlated with age (*Figure 2A*), gender (*Figure 2B*), smoking

Figure 1 The expression of *CDCA3* in pan-cancer samples. (A) Expression of *CDCA3* in pan-cancer samples from the TIMER database. (B) Expression of *CDCA3* in pan-cancer samples from the GEPIA database. (C) Expression of *CDCA3* in LUAD in the TCGA database. (D) Expression of *CDCA3* in LUAD in the GSE30219 dataset. (E) Expression of *CDCA3* in LUAD in the GSE18842 dataset. ****, P<0.0001; ***, P<0.001; **, P<0.01; *, P<0.05; ns, there exist no statistically differences. *CDCA3*, cell division cycle-associated protein-3; TIMER, Tumor Immune Estimation Resource; GEPIA, Gene Expression Profiling Interactive Analysis; LUAD, lung adenocarcinoma; TCGA, The Cancer Genome Atlas.

status (*Figure 2C*), stage (*Figure 2D*), and N (*Figure 2E*). However, no correlation was found between the expression of *CDCA3* and T (*Figure 2F*) or M (*Figure 2G*).

CDCA3 is an independent prognostic risk factor in LUAD

To further assess the prognostic potential of *CDCA3* for LUAD, Kaplan-Meier survival analysis was performed using the TCGA database and the GSE30219 and GSE31210 datasets. According to the median expression of *CDCA3* in LUAD, patients with LUAD were separated into high and low *CDCA3* expression groups. The Kaplan-Meier plot showed that higher *CDCA3* expression was related to poorer OS and DFS in TCGA OS P=0.002 (*Figure 3A*) and DFS P=0.014 (*Figure 3B*); GSE30219 OS P<0.001 (*Figure 3C*) and DFS P<0.001 (*Figure 3D*); and GSE31210

OS P<0.001 (*Figure 3E*) and DFS P<0.001 (*Figure 3F*). Moreover, an independent prognostic analysis of OS and DFS was conducted using the TCGA database and the GSE30219 and GSE31210 datasets to determine whether *CDCA3* was an independent prognostic factor for LUAD. The results of the independent prognostic analysis of OS (*Figure 4*) and DFS (*Figure 5*) showed that *CDCA3* could act as an independent prognostic factor. Univariate Cox analysis indicated that *CDCA3* could serve as an independent prognostic factor for LUAD OS and DFS based on TCGA (*Figures 4A,5A*), GSE30219 (*Figures 4C,5C*), and GSE31210 (*Figures 4E,5E*). Multivariate Cox analysis showed that *CDCA3* may be an independent prognostic factor for LUAD OS based on TCGA (*Figure 4B*) and for LUAD OS and DFS based on GSE30219 (*Figures 4D,5D*) and GSE31210 (*Figures 4F,5F*). Multivariate Cox analysis

Figure 2 The relationship between *CDCA3* expression and clinicopathological characteristics. (A) The expression of *CDCA3* was significantly correlated with age (P<0.001). (B) The expression of *CDCA3* was significantly correlated with gender (P<0.001). (C) The expression of *CDCA3* was significantly correlated with smoking (P<0.05). (D) The expression of *CDCA3* was significantly correlated with stage (P<0.01). (E) The expression of *CDCA3* was significantly correlated with N (P<0.05). (F) There was no correlation between the expression of *CDCA3* and T. (G) There were no correlation between the expression of *CDCA3* and M. ***, P<0.001; **means P<0.01; *, P<0.05; ns, there exist no statistically differences.

showed that *CDCA3* expression may not be an independent prognostic factor for DFS based on TCGA (*Figure 5B*).

Single gene GSEA of CDCA3

GSEA was performed to explore the GO and KEGG enrichment of *CDCA3*. The top 10 significantly enriched GO terms were cell cycle checkpoint signaling, cell cycle G2 M phase transition, chromosome localization, chromosome segregation, DNA conformational change, DNA dependent DNA replication, DNA geometric change, DNA reorganization, and DNA repair (*Figure 6A*). The top 10 KEGG pathways were cell cycle, proteasome, spliceosome, DNA replication, oxidative phosphorylation, pyrimidine metabolism, Parkinson's disease, oocyte meiosis, cell adhesion molecules (CAMs), and ASTHMA (*Figure 6B*). In these KEGGs, cell adhesion molecules (CAMs) and ASTHMA showed a downward trend, which means that the down regulated genes played a leading role in these two

pathways.

Relationship between CDCA3 expression and immunity

As shown in *Figure 7*, *CDCA3* expression was negatively correlated with ImmuneScore (P=4.31e-07) (*Figure 7A*), StromalScore (P=5.72e-13) (*Figure 7B*), and EstimateScore (P=5.31e-11) (Figure 7C), but positively correlated with TumorPurity (P=4.83e-10) (*Figure 7D*). Furthermore, the landscape of LUAD immune infiltrations was obtained from 520 samples after filtering in the TCGA database (*Figure 8A*). As shown in *Figure 8B,8C*, plasma cells were negatively correlated with M2 macrophages. Additionally, CIBERSORT analysis found that among 22 types of immune cells, 14 immune cells were significantly different between the high and low *CDCA3* expression groups (*Figure 8D*). Moreover, TIMER analysis showed that *CDCA3* expression was significantly correlated with 4 types of cells, they were B cells, CD4+ T cells, macrophages, and

Figure 3 Kaplan-Meier analysis of the relationship between *CDCA3* expression and OS and DFS in high and low expression groups. (A) Kaplan-Meier analysis of *CDCA3* expression and OS based on TCGA. (B) Kaplan-Meier analysis of *CDCA3* expression and DFS based on TCGA. (C) Kaplan-Meier analysis of *CDCA3* expression and OS based on GSE30219. (D) Kaplan-Meier analysis of *CDCA3* expression and DFS based on GSE30219. (E) Kaplan-Meier analysis of *CDCA3* expression and OS based on GSE31210. (F) Kaplan-Meier analysis of *CDCA3* expression and DFS based on GSE31210. *CDCA3*, cell division cycle-associated protein-3; TCGA, The Cancer Genome Atlas; OS, overall survival; DFS, disease-free survival.

dendritic cells (*Figure 8E*).

CeRNA network construction

Overall, 1969 DEmRNAs, 38 DElncRNAs, and 434 DEmiRNAs were selected between normal and LUAD samples in the TCGA database (*Figure 9A-9C*). Finally, a ceRNA network was constructed with *CDCA3*, 18 lncRNAs, and 7 miRNAs. The ceRNA network contained 26 nodes and 32 edges (*Figure 9D*).

Experimental verification

To verify the reliability of the above results, 33 LUAD tissues and 33 normal tissues were used to test *CDCA3* expression using IHC, real-time quantitative reverse transcriptase polymerase chain reaction (qRT-PCR), and WB. IHC and WB showed that the expression levels of

CDCA3 in LUAD tissues were significantly higher than those in normal tissues (*Figure 10A,10B*). Furthermore, the mRNA and protein levels of *CDCA3* were significantly higher in LUAD than in normal tissues (*Figure 10C,10D*). These experimental results were consistent with those of the bioinformatic analyses.

Discussion

LUAD is the most common pathological type of lung cancer. Tumor occurrence is inseparable from genetic factors, such as the molecular genetic basis of malignant transformation and tumor progression. In the last several years, studies on genes and proteins related to LUAD have reported valuable information about the occurrence of LUAD. Research has shown that *CDCA3* is a significant oncogene in various tumors. In BC, specific types of transcription factors can activate the expression of *CDCA3*, which then promotes


Figure 4 Multivariate and univariate Cox regression analyses indicated that *CDCA3* could serve as an independent prognostic factor for OS in LUAD based on the TCGA database and the GSE30219 and GSE31210 datasets. (A) Univariate Cox analysis of *CDCA3* expression and OS independent prognosis based on TCGA. (B) Multivariate Cox analysis of *CDCA3* expression and independent prognosis of OS based on TCGA. (C) Univariate Cox analysis of *CDCA3* expression and OS independent prognosis based on GSE30219. (D) Multivariate Cox analysis of *CDCA3* expression and independent prognosis of OS based on GSE30219. (E) Univariate Cox analysis of *CDCA3* expression and OS independent prognosis based on GSE31210. (F) Multivariate Cox analysis of *CDCA3* expression and independent prognosis of OS based on GSE31210. *CDCA3*, cell division cycle-associated protein-3; OS, overall survival; LUAD, lung adenocarcinoma; TCGA, The Cancer Genome Atlas; DFS, disease-free survival.

the proliferation of BC cells, such as kinesin family member 22 (KIF22) and KIF4A. Similarly, research has shown that *CDCA3* promotes cell cycle progression, accelerates cell growth, and promotes BC cell migration (11,18,19). Moreover, *CDCA3* is a biomarker of chemosensitivity in NSCLC. A high expression level of *CDCA3* improves sensitivity to platinum chemotherapy, and upregulation of *CDCA3* expression may enhance the sensitivity of tyrosine kinase inhibitor (TKI) in epidermal growth factor

receptor (EGFR)-mutant lung cancer (13,20). KIRP and breast cancer present the same finding. *CDCA3* not only participates in cell cycle regulation but also promotes doxorubicin resistance in breast cancer and enhances sensitivity to platinum-based chemotherapy in NCSLC (20-22). However, controversial outcomes still exist; for example, knockdown of *CDCA3* in NCSLC reduces the proliferation of NCSLC cells by stagnating them in G2/M phase (23). In colorectal cancer (CRC) and PC, *CDCA3*

Figure 5 Multivariate and univariate Cox regression analyses indicated that *CDCA3* could serve as an independent prognostic factor for DFS in LUAD based on the GSE30219 and GSE31210 datasets. (A) Univariate Cox analysis of *CDCA3* expression and DFS independent prognosis based on TCGA. (B) Multivariate Cox analysis showed that *CDCA3* expression may not be an independent prognosis of DFS based on TCGA. (C) Univariate Cox analysis of *CDCA3* expression and DFS independent prognosis based on GSE30219. (D) Multivariate Cox analysis of *CDCA3* expression and independent prognosis of DFS based on GSE30219. (E) Univariate Cox analysis of *CDCA3* expression and DFS independent prognosis based on GSE31210. (F) Multivariate Cox analysis of expression of *CDCA3* and independent prognosis of DFS based on GSE31210. *CDCA3*, cell division cycle-associated protein-3; DFS, disease-free survival; LUAD, lung adenocarcinoma; TCGA, The Cancer Genome Atlas.

induces cell cycle arrest in the G1 phase (24,25). In addition, *CDCA3* also affects the progression of GC through epigenetics. DNA hypomethylation promotes the expression of *CDCA3* and the invasion and metastasis of GC cells by regulating the binding of Sp1 transcription factor (Sp1) to the *CDCA3* promoter. Similarly, another study found that the overexpression of *CDCA3* leads to the continuous activation of the Ras pathway and induces the abnormal activation of the extracellular signal-regulated kinase (ERK)/

mitogen-activated protein kinase (MAPK) signaling pathway, which leads to the occurrence of GC (10,26).

The clinical application of immunotherapy has shifted the focus of tumor treatment from tumor cells to the tumor microenvironment (27). Based on CIBERSORT bioinformatics analysis, our study found that 14 of 22 types of immune cells had significant differences in the high and low *CDCA3* expression groups, including memory B cells, activated mast cells (P<0.05), follicular helper T cells,

Figure 6 GSEA enrichment of *CDCA3* in LUAD. (A) Top 10 significantly enriched GO terms. (B) Top 10 KEGG pathways. GSEA, Gene Set Enrichment Analysis; *CDCA3*, cell division cycle-associated protein-3; LUAD, lung adenocarcinoma; GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes.


Figure 7 The relationship between *CDCA3* expression and immune score. (A) *CDCA3* expression was negatively correlated with ImmuneScore. (B) *CDCA3* expression was negatively correlated with StromalScore. (C) *CDCA3* expression was negatively correlated with EstimateScore. (D) *CDCA3* expression was positively correlated with TumorPurity. *CDCA3*, cell division cycle-associated protein-3.

2912

Yang et al. To explore the role of CDCA3 in lung adenocarcinoma

Figure 8 Analysis of immune cell infiltration between high and low *CDCA3* expression groups. (A) CIBERSORT heatmap of the proportion of 22 types of infiltrating immune cells. (B) The correlation heatmap of the proportion of 22 immune cells. Red indicates positive correlation, blue indicates negative correlation, and the darker the color, the stronger the positive/negative correlation. (C) The correlation P value heatmap of immune cell proportions. (D) The box diagram of immune cell differences in high and low expression groups. Fourteen kinds of immune cells were significantly different. (E) Scatter plot of the correlation between *CDCA3* expression and 6 immune cells based on TIMER. ****, P<0.0001; ***, P<0.001; **, P<0.01; *, P<0.05; ns, there exist no statistically differences between this two groups.

Figure 9 Construction of a ceRNA network based on *CDCA3*. (A) Volcano map of differential mRNAs expression based on TCGA. (B) Volcano map of differential lncRNA expression based on TCGA. (C) Volcano map of differential miRNA expression based on TCGA. (D) lncRNA-miRNA-*CDCA3* network. The triangle, diamond, and circle indicate lncRNA, miRNA, and mRNA, respectively. Color indicates the expression trend, with red indicating upregulated genes, blue indicating downregulated genes, and gray indicating no differentially expressed genes. ceRNA, competitive endogenous RNA; *CDCA3*, cell division cycle-associated protein-3; TCGA, The Cancer Genome Atlas; lncRNA, long noncoding RNA; miRNA, microRNA.

activated NK cells (P<0.01), CD8 T cells, CD4 memory resting T cells, CD4 memory activated T cells, resting NK cells, monocytes, M0 macrophages, M1 macrophages, resting dendritic cells, activated dendritic cells, and resting mast cells (P<0.001). Previous studies have also reported a correlation between *CDCA3* and immune cell infiltration in HCC involving B cells, neutrophils, monocytes, tumor-associated macrophages (TAMs), M1 and M2 macrophages, CD4+ T cells, CD8+ T cells, NK cells, and dendritic cells (8). In the TIMER database, we found a significant correlation between the expression of *CDCA3* and 4 types of immune cells, namely B cells, CD4+ T cells, macrophages,

and dendritic cells (P values were 7.17e-06, 1.55e-02, 1.31e-03, and 9.95e-03, respectively). This was consistent with our previous CIBERSORT results. Moreover, *CDCA3* is also regulated by noncoding RNA, which affects the occurrence of tumors. CeRNA is a key regulatory mechanism (28). LncRNA or circular RNA (circRNA) compete for binding to miRNA, and then the transcription level of target genes regulated by miRNA are upregulated. Many studies have reported on this mechanism, such as circRNA-miRNA-*CDCA3* or LncRNA-miRNA-*CDCA3* (29). CirRNA hsa_circ_101555, hsa_circ_0005728, and Circ_0001421 via the miR-145-5p/*CDCA3*, miR-512-3p/CDCA3, and miR-

　　　　　　　　　　　　　　　　Transl Cancer Res 2022;11(8):2902-2916 | https://dx.doi.org/10.21037/tcr-22-1901

Figure 10 Validation of clinical tissue samples. (A) IHC of *CDCA3* in LUAD and normal lung tissue (×20). (B) WB results of *CDCA3* in LUAD and normal lung tissue. (C) The protein expression of *CDCA3* in LUAD and normal lung tissue. (D) The relative mRNA expression of *CDCA3* in LUAD and normal lung tissue. IHC, immunohistochemistry; *CDCA3*, cell division cycle-associated protein-3; LUAD, lung adenocarcinoma; mRNA, messenger RNA; WB, western blotting. ****, $P < 0.0001$.

4677-3p/*CDCA3* axis is a ceRNA network that boosts proliferation and migration in HCC, BC, and LC (21,30,31). LncRNA LINC00707 accelerates the development and progression of BC by targeting miR-145/*CDCA3* (22). Our study predicted the target non-coding RNAs, including 18 lncRNAs and 7 miRNAs, and then constructed a ceRNA network. Next, we verified the binding between target genes and the screened RNA through a series of experiments to explore the mechanism.

GO functional analysis indicated that *CDCA3* may participate in processes such as cell division, apoptosis, DNA damage, and DNA repair and may participate in tumor progression through cell cycle G2 M phase transition, as shown in *Figure 6A*. This result is consistent with previous report (23). KEGG pathway analysis indicated that *CDCA3*

was involved in cell cycle, proteasome, spliceosome, and DNA replication pathways. Studies have shown that *CDCA3* activates the nuclear factor kappa B (NF-KB)/cyclin D1 signaling pathway and promotes cancer cell proliferation in CRC and PC (25). In breast cancer and pancreatic cancer, *CDCA3* plays a critical role in tumor progression through activation of the phosphoinositide 3-kinases (PI3K)/AKT pathway (7,32). The above pathways were included in our KEGG analysis results, which are consistent with previous reports.

In this study, we explored the expression of *CDCA3* in LUAD from multiple angles through a bioinformatics analysis. First, we investigated the correlation between this gene and clinicopathological parameters. Next, we analyzed the independent prognosis and tumor microenvironment

of LUAD and constructed a ceRNA network of *CDCA3*. Moreover, we preliminarily verified the bioinformatics results using relevant experiments. Generally speaking, our findings are consistent with previous results on *CDCA3* in tumors and provide a theoretical basis for further exploration of the role of *CDCA3* in the occurrence of LUAD. However, our study had some limitations. The function of *CDCA3* requires further exploration in follow-up experiments *in vivo* and *in vitro* to confirm its role in the preliminary screening and early diagnosis of LUAD.

Conclusions

In brief, our results showed that the expression of *CDCA3* was upregulated in a variety of cancers, including LUAD, and was significantly correlated with several clinical parameters. The high expression of *CDCA3* was negatively correlated with OS and DFS. Univariate and multivariate Cox regression analysis indicated that *CDCA3* could be used as an independent prognostic factor of LUAD. In addition, we also analyzed the relationship between *CDCA3* and the tumor immune microenvironment and found that its expression was related to certain immune cells. The above results might provide a theoretical basis for further study.

Acknowledgments

Footnote

Reporting Checklist: The authors have completed the REMARK reporting checklist. Available at https://tcr.amegroups.com/article/view/10.21037/tcr-22-1901/rc

Data Sharing Statement: Available at https://tcr.amegroups.com/article/view/10.21037/tcr-22-1901/dss

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tcr.amegroups.com/article/view/10.21037/tcr-22-1901/coif). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). The study was approved by the Ethics Committee of The Second Affiliated Hospital of Kunming Medical University (No. KYCS2022090) and informed consent was obtained from all patients.

References

1. Hu J, Chen Y, Li X, et al. THUMPD3-AS1 Is Correlated With Non-Small Cell Lung Cancer And Regulates Self-Renewal Through miR-543 And ONECUT2. Onco Targets Ther 2019;12:9849-60.

2. Zou Y, Jing C, Liu L, et al. Serum microRNA-135a as a diagnostic biomarker in non-small cell lung cancer. Medicine (Baltimore) 2019;98:e17814.

3. Miller KD, Nogueira L, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin 2019;69:363-85.

4. Gao S, Li N, Wang S, et al. Lung Cancer in People's Republic of China. J Thorac Oncol 2020;15:1567-76.

5. Hutchinson BD, Shroff GS, Truong MT, et al. Spectrum of Lung Adenocarcinoma. Semin Ultrasound CT MR 2019;40:255-64.

6. Bade BC, Dela Cruz CS. Lung Cancer 2020: Epidemiology, Etiology, and Prevention. Clin Chest Med 2020;41:1-24.

7. Xing C, Wang Z, Zhu Y, et al. Integrate analysis of the promote function of Cell division cycle-associated protein family to pancreatic adenocarcinoma. Int J Med Sci 2021;18:672-84.

8. Wang Z, Chen S, Wang G, et al. CDCA3 Is a Novel Prognostic Biomarker Associated with Immune Infiltration in Hepatocellular Carcinoma. Biomed Res Int 2021;2021:6622437.

9. Wu B, Huang Y, Luo Y, et al. The diagnostic and

prognostic value of cell division cycle associated gene family in Hepatocellular Carcinoma. J Cancer 2020;11:5727-37.

10. Zhang Y, Yin W, Cao W, et al. CDCA3 is a potential prognostic marker that promotes cell proliferation in gastric cancer. Oncol Rep 2019;41:2471-81.

11. Li S, Liu X, Liu T, et al. Identification of Biomarkers Correlated with the TNM Staging and Overall Survival of Patients with Bladder Cancer. Front Physiol 2017;8:947.

12. Gu P, Yang D, Zhu J, et al. Bioinformatics analysis of the clinical relevance of CDCA gene family in prostate cancer. Medicine (Baltimore) 2022;101:e28788.

13. Sahin KB, Shah ET, Ferguson GP, et al. Elevating CDCA3 Levels Enhances Tyrosine Kinase Inhibitor Sensitivity in TKI-Resistant EGFR Mutant Non-Small-Cell Lung Cancer. Cancers (Basel) 2021;13:4651.

14. Yu G, Wang LG, Han Y, et al. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS 2012;16:284-7.

15. Du J, Tao Q, Liu Y, et al. Assessment of the targeted effect of Sijunzi decoction on the colorectal cancer microenvironment via the ESTIMATE algorithm. PLoS One 2022;17:e0264720.

16. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004;3:Article3.

17. Villanueva RAM, Chen ZJ. ggplot2: Elegant Graphics for Data Analysis (2nd ed.). Measurement: Interdisciplinary Research and Perspectives 2019;17:160-7.

18. Li K, Li S, Tang S, et al. KIF22 promotes bladder cancer progression by activating the expression of CDCA3. Int J Mol Med 2021;48:211.

19. Zheng P, Wu K, Gao Z, et al. KIF4A promotes the development of bladder cancer by transcriptionally activating the expression of CDCA3. Int J Mol Med 2021;47:99.

20. Kildey K, Gandhi NS, Sahin KB, et al. Elevating CDCA3 levels in non-small cell lung cancer enhances sensitivity to platinum-based chemotherapy. Commun Biol 2021;4:638.

21. Dou D, Ren X, Han M, et al. CircUBE2D2 (hsa_circ_0005728) promotes cell proliferation, metastasis and chemoresistance in triple-negative breast cancer by regulating miR-512-3p/CDCA3 axis. Cancer Cell Int 2020;20:454.

22. Gao T, Ji Y. Long Noncoding RNA LINC00707 Accelerates Tumorigenesis and Progression of Bladder Cancer via Targeting miR-145/CDCA3 Regulatory Loop. Urol Int 2021;105:891-905.

23. Adams MN, Burgess JT, He Y, et al. Expression of CDCA3 Is a Prognostic Biomarker and Potential Therapeutic Target in Non-Small Cell Lung Cancer. J Thorac Oncol 2017;12:1071-84.

24. Qian W, Zhang Z, Peng W, et al. CDCA3 mediates p21-dependent proliferation by regulating E2F1 expression in colorectal cancer. Int J Oncol 2018;53:2021-33.

25. Gu P, Zhang M, Zhu J, He X, Yang D. Suppression of CDCA3 inhibits prostate cancer progression via NF-κB/ cyclin D1 signaling inactivation and p21 accumulation. Oncol Rep 2022;47:42.

26. Yu J, Hua R, Zhang Y, et al. DNA hypomethylation promotes invasion and metastasis of gastric cancer cells by regulating the binding of SP1 to the CDCA3 promoter. J Cell Biochem 2020;121:142-51.

27. Nadal E, Massuti B, Dómine M, et al. Immunotherapy with checkpoint inhibitors in non-small cell lung cancer: insights from long-term survivors. Cancer Immunol Immunother 2019;68:341-52.

28. Fei X, Hu C, Wang X, et al. Construction of a Ferroptosis-Related Long Non-coding RNA Prognostic Signature and Competing Endogenous RNA Network in Lung Adenocarcinoma. Front Cell Dev Biol 2021;9:751490.

29. Yang J, Hao R, Zhang Y, et al. Construction of circRNA-miRNA-mRNA network and identification of novel potential biomarkers for non-small cell lung cancer. Cancer Cell Int 2021;21:611.

30. Gu X, Zhang J, Ran Y, et al. Circular RNA hsa_circ_101555 promotes hepatocellular carcinoma cell proliferation and migration by sponging miR-145-5p and regulating CDCA3 expression. Cell Death Dis 2021;12:356.

31. Zhang K, Hu H, Xu J, et al. Circ_0001421 facilitates glycolysis and lung cancer development by regulating miR-4677-3p/CDCA3. Diagn Pathol 2020;15:133.

32. Du WW, Yang W, Li X, et al. The Circular RNA circSKA3 Binds Integrin β1 to Induce Invadopodium Formation Enhancing Breast Cancer Invasion. Mol Ther 2020;28:1287-98.

(English Language: C. Gourlay)